| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | 25,411,055 |
| Depreciation and amortization | 3,885,153 |
| Non-cash lease expense, net of lease payments | 5,812 |
| Share-based payments for services | 754,673 |
| Equity based compensation | 1,910,997 |
| Common stock contributed to 401 plan | 218,317 |
| Shares issued for settlement of clinic development costs | 350,885 |
| Loss on patent impairment | 18,275 |
| Prepaid expenses | 42,550 |
| Supplies used for r&d and manufacturing | -973,665 |
| Deposits | 3,585 |
| Accounts payable | -442,710 |
| Accrued expenses | 120,728 |
| Due to employees | 553,282 |
| Net cash used in operating activities | -17,119,737 |
| Purchases of property and equipment | 38,109 |
| Expenditures for patent costs | 0 |
| Net cash used in investing activities | -38,109 |
| Proceeds from issuance of common stock and pre-funded warrants | 28,291,100 |
| Payments of stock issuance costs | 3,126,779 |
| Proceeds from the purchase of stock by officers and directors | -219,995 |
| Payments on obligations under finance leases | 2,011,183 |
| Proceeds from related party loans | 0 |
| Payments of related party loans | 0 |
| Proceeds from notes payable | 350,000 |
| Payments of notes payable | 350,000 |
| Net cash provided by financing activities | 23,373,133 |
| Net increase in cash and cash equivalents | 6,215,287 |
| Cash and cash equivalents at beginning of period | 4,738,173 |
| Cash and cash equivalents at end of period | 10,953,460 |
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)